Search

Your search keyword '"Gerbitz, Armin"' showing total 15 results
Start Over Author "Gerbitz, Armin" Publisher wiley
15 results on '"Gerbitz, Armin"'

1. Letermovir prophylaxis for cytomegalovirus reactivation in allogeneic hematopoietic cell transplant recipients: Single center Canadian data

Author

Pang, Ian, primary, Chen, Peggy, additional, Trinh, Gertrude V., additional, Remberger, Mats, additional, Novitzky‐Basso, Igor, additional, Gerbitz, Armin, additional, Kim, Dennis D., additional, Kumar, Rajat, additional, Lam, Wilson, additional, Law, Arjun D., additional, Lipton, Jeffrey H., additional, Viswabandya, Auro, additional, Pasic, Ivan, additional, Mattsson, Jonas, additional, and Michelis, Fotios V., additional

Published
2023
Full Text
View/download PDF

2. Influence of conditioning regimen intensity on outcomes post‐allogeneic hematopoietic cell transplantation for acute myeloid leukemia in complete morphological remission

Author

Alfaro Moya, Tommy, primary, Mattsson, Jonas, additional, Remberger, Mats, additional, Lipton, Jeffrey H., additional, Kim, Dennis D., additional, Viswabandya, Auro, additional, Kumar, Rajat, additional, Lam, Wilson, additional, Law, Arjun D., additional, Gerbitz, Armin, additional, Pasic, Ivan, additional, Novitzky‐Basso, Igor, additional, and Michelis, Fotios V., additional

Published
2023
Full Text
View/download PDF

3. The 17‐gene stemness score associates with relapse risk and long‐term outcomes following allogeneic haematopoietic cell transplantation in acute myeloid leukaemia

Author

Kim, Dennis D. H., primary, Novitzky Basso, Igor, additional, Kim, Taehyung Simon, additional, Yi, Seong Yoon, additional, Kim, Kyoung Ha, additional, Murphy, Tracy, additional, Chan, Steven, additional, Minden, Mark, additional, Pasic, Ivan, additional, Lam, Wilson, additional, Law, Arjun, additional, Michelis, Fotios V., additional, Gerbitz, Armin, additional, Viswabandya, Auro, additional, Lipton, Jeffrey, additional, Kumar, Rajat, additional, Ng, Stanley W. K., additional, Stockley, Tracy, additional, Zhang, Tong, additional, King, Ian, additional, Mattsson, Jonas, additional, and Wang, Jean C. Y., additional

Published
2022
Full Text
View/download PDF

4. Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Therapy‐Related Hematologic Malignancies Developing After Multiple Myeloma.

Author

Vasudevan Nampoothiri, Ram, primary, Pasic, Ivan, additional, Law, Arjun Datt, additional, Lam, Wilson, additional, Chen, Carol, additional, Michelis, Fotios V., additional, Kim, Dennis (Dong Hwan), additional, Gerbitz, Armin, additional, Lipton, Jeffrey Howard, additional, Kumar, Rajat, additional, Mattsson, Jonas, additional, and Viswabandya, Auro, additional

Published
2022
Full Text
View/download PDF

5. Anti‐thymocyte Globulin and Post‐Transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen‐A and ‐B mismatched donors

Author

Novitzky‐Basso, Igor, primary, Remberger, Mats, additional, Chen, Carol, additional, Ellison, Cynthia, additional, Pasic, Ivan, additional, Lam, Wilson, additional, Law, Arjun, additional, Gerbitz, Armin, additional, Viswabandya, Auro, additional, Lipton, Jeffrey H., additional, Kim, Dennis D., additional, Kumar, Rajat, additional, Michelis, Fotios V., additional, and Mattsson, Jonas, additional

Published
2021
Full Text
View/download PDF

6. Anti‐thymocyte globulin and post‐transplant cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts

Author

Novitzky‐Basso, Igor, primary, Remberger, Mats, additional, Chen, Carol, additional, Pasić, Ivan, additional, Lam, Wilson, additional, Law, Arjun, additional, Gerbitz, Armin, additional, Viswabandya, Auro, additional, Lipton, Jeffrey H., additional, Kim, Dennis D., additional, Kumar, Rajat, additional, Mattsson, Jonas, additional, and Michelis, Fotios V., additional

Published
2021
Full Text
View/download PDF

7. Pretransplant bone marrow cellularity and blood count recovery are not associated with relapse or survival risk following allogeneic stem cell transplant for AML in CR

Author

Novitzky‐Basso, Igor, primary, Chen, Carol, additional, Chen, Shiyi, additional, Lipton, Jeffrey H., additional, Kim, Dennis D., additional, Viswabandya, Auro, additional, Kumar, Rajat, additional, Lam, Wilson, additional, Law, Arjun, additional, Al‐Shaibani, Zeyad, additional, Gerbitz, Armin, additional, Pasic, Ivan, additional, Mattsson, Jonas, additional, and Michelis, Fotios V., additional

Published
2021
Full Text
View/download PDF

8. Anti‐thymocyte globulin and post‐transplant cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts

Author

Novitzky‐Basso, Igor, Remberger, Mats, Chen, Carol, Pasić, Ivan, Lam, Wilson, Law, Arjun, Gerbitz, Armin, Viswabandya, Auro, Lipton, Jeffrey H., Kim, Dennis D., Kumar, Rajat, Mattsson, Jonas, Michelis, Fotios V., Novitzky‐Basso, Igor, Remberger, Mats, Chen, Carol, Pasić, Ivan, Lam, Wilson, Law, Arjun, Gerbitz, Armin, Viswabandya, Auro, Lipton, Jeffrey H., Kim, Dennis D., Kumar, Rajat, Mattsson, Jonas, and Michelis, Fotios V.

Abstract

During 2020, the concurrent novel COVID-19 pandemic lead to widespread cryopreservation of allogeneic hematopoietic cell transplant grafts based on National Marrow Donor Program and European Society of Blood and Marrow Transplantation recommendations, in order to secure grafts before the start of conditioning chemotherapy. We sought to examine the impact of this change in practice on patient outcomes. We analyzed the outcomes of 483 patients who received hematopoietic stem cell transplantation (HSCT) between August 2017 and August 2020, at Princess Margaret Cancer Centre, Canada, in the retrospective study, comparing the outcomes between those who received cryopreserved or fresh peripheral blood stem cell grafts. Overall compared with those who received fresh grafts (n = 348), patients who received cryopreserved grafts (n = 135) had reduced survival and GRFS, reduced incidence of chronic graft-versus-host disease (GvHD), delay in neutrophil engraftment, and higher graft failure (GF), with no significant difference in relapse incidence or acute GvHD. However, recipients of cryopreserved matched-related donor HSCT showed significantly worse OS, NRM, GRFS compared with fresh grafts. Multivariable analysis of the entire cohort showed significant impact of cryopreservation on OS, relapse, cGvHD, GF, and GRFS. We conclude that cryopreservation was associated with inferior outcomes post-HSCT, possibly due to the combination of ATG and post-transplant cyclophosphamide impacting differential tolerance to cryopreservation on components of the stem cell graft; further studies are warranted to elucidate mechanisms for this observation.

Published
2021
Full Text
View/download PDF

9. Refined hepatic grading system in chronic graft‐versus‐host disease improves prognostic risk stratification of long‐term outcomes

Author

Novitzky‐Basso, Igor, primary, AlHayli, Saud, additional, Shin, Elizabeth, additional, Pasic, Ivan, additional, Al‐Shaibani, Zeyad, additional, Lam, Wilson, additional, Law, Arjun, additional, Michelis, Fotios V., additional, Gerbitz, Armin, additional, Viswabandya, Auro, additional, Lipton, Jeffrey H., additional, Kumar, Rajat, additional, Mattsson, Jonas, additional, and Kim, Dennis Dong Hwan, additional

Published
2021
Full Text
View/download PDF

10. Post‐transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA‐identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Author

Battipaglia, Giorgia, primary, Labopin, Myriam, additional, Hamladji, Rose‐Marie, additional, Blaise, Didier, additional, Chevallier, Patrice, additional, Brissot, Eolia, additional, Gerbitz, Armin, additional, Socié, Gerard, additional, Afanasyev, Boris, additional, Ciceri, Fabio, additional, Meijer, Ellen, additional, Koc, Yener, additional, Cornelissen, Jan J., additional, Huynh, Anne, additional, Ozdogu, Hakan, additional, Maertens, Johan, additional, Paul, Franciane, additional, Labussière‐Wallet, Hélène, additional, Ruggeri, Annalisa, additional, Aljurf, Mahmoud, additional, Bazarbachi, Ali, additional, Savani, Bipin, additional, Nagler, Arnon, additional, and Mohty, Mohamad, additional

Published
2020
Full Text
View/download PDF

11. Prolactin, a potential biomarker for chronic GVHD activity

Author

Salas, Maria Queralt, primary, Ezzat, Shereen, additional, Lam, Wilson, additional, Law, Arjun Datt, additional, Pasic, Ivan, additional, Michelis, Fotios V., additional, Kim, Dennis Dong Hwan, additional, Gerbitz, Armin, additional, Al‐Shaibani, Zeyad, additional, Viswabandya, Auro, additional, Kumar, Rajat, additional, Mattsson, Jonas, additional, and Lipton, Jeffrey Howard, additional

Published
2020
Full Text
View/download PDF

12. Clinical prevalence and outcome of cardiovascular events in the first 100 days postallogeneic hematopoietic stem cell transplant

Author

Alblooshi, Rehab, primary, Kanfar, Solaf, additional, Lord, Bridgette, additional, Atenafu, Eshetu G., additional, Michelis, Fotios V., additional, Pasic, Ivan, additional, Gerbitz, Armin, additional, Al‐Shaibani, Zeyad, additional, Viswabandya, Auro, additional, Kim, Dennis (Dong Hwan), additional, Lam, Wilson, additional, Law, Arjun, additional, Mattsson, Jonas, additional, Kumar, Rajat, additional, and Lipton, Jeffrey H., additional

Published
2020
Full Text
View/download PDF

13. Targeting high-grade B cell lymphoma with CD19-specific T cells

Author

Lehmann, Frank M., primary, Maurberger, Anna, additional, Feicht, Samantha, additional, Helm, Florian, additional, Ladinig, Camilla, additional, Kieback, Elisa, additional, Uckert, Wolfgang, additional, Kammertöns, Thomas, additional, Kremmer, Elisabeth, additional, Mautner, Josef, additional, Gerbitz, Armin, additional, and Bornkamm, Georg W., additional

Published
2014
Full Text
View/download PDF

15. Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Author

Battipaglia G, Labopin M, Hamladji RM, Blaise D, Chevallier P, Brissot E, Gerbitz A, Socié G, Afanasyev B, Ciceri F, Meijer E, Koc Y, Cornelissen JJ, Huynh A, Ozdogu H, Maertens J, Paul F, Labussière-Wallet H, Ruggeri A, Aljurf M, Bazarbachi A, Savani B, Nagler A, and Mohty M

Subjects
Adolescent, Adult, Aged, Feasibility Studies, Female, Follow-Up Studies, Graft vs Host Disease epidemiology, Humans, Incidence, Male, Middle Aged, Retrospective Studies, Transplantation, Homologous methods, Treatment Outcome, Young Adult, Antilymphocyte Serum administration & dosage, Blood Donors, Cyclophosphamide administration & dosage, Graft vs Host Disease prevention & control, HLA Antigens immunology, Hematopoietic Stem Cell Transplantation adverse effects, Hematopoietic Stem Cell Transplantation methods, Immunosuppressive Agents administration & dosage, Leukemia, Myeloid, Acute surgery, Siblings
Abstract

Background: Graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Addition of antithymocyte globulin (ATG) or post-transplantation cyclophosphamide (PTCY) to standard immunosuppressive agents reduces GVHD in different donor settings., Methods: We compared the outcomes of adults with acute myeloid leukemia undergoing allo-HSCT from HLA-identical sibling donors after the use of PTCY (n = 197) or ATG (n = 1913)., Results: Patients in the PTCY group were younger than those in the ATG group (median age, 47 vs 54 years; P < .01). Peripheral blood was the most frequently used stem cell source, being significantly more frequent in the ATG group than in the PTCY group (95% vs 70% P < .01). The conditioning regimen was more frequently myeloablative in the PTCY group than in the ATG group (59% vs 48%; P < .01). Time to neutrophil engraftment was shorter in the ATG group than in the PTCY group (17 vs 20 days; P < .01). No differences were observed according to the other transplantation outcomes, except for chronic GVHD of all grades and extensive chronic GVHD at 2 years, which were significantly lower in the ATG group compared with the PTCY group (P < .02)., Conclusion: PTCY is feasible in an HLA-identical sibling setting, and despite similar outcomes, ATG may be associated with lower incidence of chronic GVHD., (© 2020 American Cancer Society.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results